The Romanian Competition Authority imposes a fine totaling €2.5 million on a pharmaceutical company for failure to observe commitments in an abuse of dominance probe (GlaxoSmithKline)

The Romanian Competition Authority announced on 25 August 2020 that it imposed a fine of 11.9 million lei (approximately EUR 2.5 million)

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)

Quotation

Peter L'Ecluse, Catherine Longeval, Koen T'Syen, The Romanian Competition Authority imposes a fine totaling €2.5 million on a pharmaceutical company for failure to observe commitments in an abuse of dominance probe (GlaxoSmithKline), 25 August 2020, e-Competitions Remedies for unilateral conduct, Art. N° 96573

Visites 906

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues